Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of July 2015, with a report date of July 8, 2015. The document serves as an English translation of an immediate report submitted to the Tel-Aviv Stock Exchange and the Israeli Securities Authority regarding changes in significant shareholdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on equity ownership changes rather than operational or financial performance.
Material Changes
The filing details significant reductions in shareholdings by IBI Investment House Ltd. across two distinct capacities:
- Market Maker Capacity: The holder reduced its position by 8,880 shares, decreasing the balance from 8,880 to 0 shares (0.00% ownership).
- Management Companies of Mutual Investment Trust Funds: The holder reduced its position by 224,927 shares, decreasing the balance from 9,290,757 to 9,065,830 shares. The holding percentage ranged between 3.76% and 3.85% during the period.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for management guidance, future outlook, specific risks, contingencies, or unusual items. The document is a regulatory disclosure of shareholder activity and contains no management commentary on business strategy or financial projections.
Investor Verification Checklist
- Verify the correct registrant name is BiondVax Pharmaceuticals Ltd., as the request metadata incorrectly listed Scinai Immunotherapeutics Ltd.
- Confirm the total reduction in shares held by IBI Investment House Ltd. (233,807 shares total across both capacities).
- Review the fully diluted basis calculation for the 3.76% to 3.85% ownership range.
- Check subsequent filings for any operational or financial updates, as this 6-K contains no financial data.